$AMGN EVENITY romosozumab Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

$AMGN EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

16:04 EST 8 Jan 2019 | Odi Bruckman

$AMGN EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

More From BioPortfolio on "$AMGN EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture"